NDAORALTABLET
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults
Started Aug 2026
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Started Oct 2025
30 enrolled
Chronic Graft Versus Host Disease
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
Started Dec 2024
Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
Started Oct 2021
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Started May 2021
Loss of Exclusivity
LOE Date
Jul 27, 2032
77 months away
Patent Expiry
Jul 27, 2032